Chemo Tied to Long-Lasting Physical Health Decline for Breast Cancer Survivors
By Elana Gotkine HealthDay Reporter
WEDNESDAY, March 5, 2025 -- Breast cancer (BC) survivors who receive chemotherapy may experience greater physical health decline than those who receive endocrine therapy alone, according to a study published online Feb. 28 in JAMA Network Open.
Clara Bodelon, Ph.D., from the American Cancer Society in Atlanta, and colleagues conducted a prospective cohort study of participants in 35 states, the District of Columbia, and Puerto Rico between 2006 and 2013 to examine physical health decline in BC survivors who received chemotherapy or endocrine therapy compared with age-matched women without cancer. Data were included for 2,566 women diagnosed with BC and 12,826 women without cancer.
Of the women with BC, 47.7, 10.8, and 24.7 percent received endocrine therapy, chemotherapy, and both, respectively. The researchers found greater physical health decline within two years of diagnosis for BC survivors receiving endocrine therapy, chemotherapy, or both (β = −1.12, −3.13, and −3.26, respectively). The decline among endocrine therapy users was only seen in women receiving aromatase inhibitors. More than two years after diagnosis, only women who received chemotherapy experienced a decline in physical health.
"Understanding the survivorship care needs and management of late effects in BC survivors is critical," the authors write. "Continued efforts are needed to understand the specific survivorship care needs of BC survivors and improve their long-term quality of life."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted March 2025
Read this next
32 Percent of U.S. Adults Consumed Fast Food on a Given Day in 2021 to 2023
FRIDAY, June 27, 2025 -- Over 30 percent of adults and children consumed fast food on a given day during August 2021 to August 2023, according to two reports from the National...
Disparities Seen in Continuous Glucose Monitor Rx by Language Preference
FRIDAY, June 27, 2025 -- For patients with type 2 diabetes (T2D), disparities in continuous glucose monitor (CGM) prescriptions are seen by language preference, with less access...
Survey Shows Few Adults Recognize Testicular Cancer as Affecting Young Men
FRIDAY, June 27, 2025 -- Only one in 10 U.S. adults correctly identified testicular cancer as most commonly affecting men under age 40, according to a survey released June16 by...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.